艾灸免疫调节的局部作用机制研究
|
摘要
目的：分别以免疫低下和免疫紊乱为研究对象,探讨艾灸免疫调节作用的局部作用机制。
方法：(1)采用D-半乳糖注射形成的亚急性衰老模型为艾灸免疫低下调节载体,给予背部膀胱经肺俞-肾俞施灸,检测血清皮质酮含量及施灸部位皮肤MHC-Ⅱ、IL-12、CD-80、波形蛋白的表达；(2)采用完全弗氏佐剂注射造模佐剂性关节炎为免疫紊乱研究载体,给予艾灸“足三里”,以足跖肿胀改善、血清TNF-α、IL-1β、IL-10变化为艾灸免疫紊乱调节指标,并同时检测艾灸局部、脾脏、胸腺、下丘脑瘦素及瘦素受体表达和血清瘦素含量变化。结果：(1)D-半乳糖造模形成的衰老模型大鼠血清皮质酮含量高于对照组,差异具有统计学意义,p<0.01；艾灸组血清皮质酮含量低于模型组,p<0.01。模型组皮肤MHC-Ⅱ、IL-12、CD80、波形蛋白表达阳性细胞数少于空白组,表达强度也低于空白组,p<0.01；艾灸组施灸部位皮肤MHC-Ⅱ、IL-12、CD80、波形蛋白表达阳性细胞数多于模型组,表达强度也高于空白组,p<0.01。(2)艾灸组足跖肿胀程度从开始接受治疗后一直呈逐步下降趋势,在第7天与模型组相比,有显著差异(p<0.05),到第14天时,差异更为显著(p<0.01)。模型组TNF-α、IL-1β含量显著高于对照组,p<0.01；艾灸组的TNF-α、IL-1β含量显著低于对照组,p<0.01。模型组IL-10含量显著高于对照组,p<0.01；艾灸组的工L-10含量也显著高于对照组,p<0.01。模型组穴位局部瘦素、瘦素受体表达阳性细胞数少于空白组,表达强度也低于空白组,p<0.01;艾灸组穴位局部皮肤瘦素、瘦素受体表达阳性细胞数多于模型组,表达强度也高于空白组,p<0.01。模型组血清瘦素含量显著低于对照组,p<0.01；艾灸组血清瘦素含量显著高于对照组,p<0.05。模型组大鼠脾脏、胸腺瘦素、瘦素受体表达阳性细胞数、表达强度与空白组比较,差异没有统计学意义,P>0.05；艾灸组脾脏、胸腺瘦素、瘦素受体表达阳性细胞数、表达强度与模型组比较,差异也没有统计学意义,p>0.05。模型组大鼠下丘脑瘦素、瘦素受体表达阳性细胞数多于对照组,p<0.01,表达强度也高于空白组,p<0.01；艾灸组下丘脑瘦素、瘦素受体表达阳性细胞数多于模型组,P<0.01,表达强度也高于模型组,p<0.05。
结论：(1)艾灸可纠正衰老低下的免疫状态,可能与艾灸施术部位的MHC-Ⅱ、IL-12、CD80及波形蛋白的皮肤免疫激活有关；(2)艾灸可调整佐剂性关节炎模型紊乱的免疫功能,可能与下丘脑和穴位局部的瘦素、瘦素受体的表达增强有关；(3)艾灸对免疫调节的局部作用机制可能与神经免疫网络一起,形成艾灸调节免疫的皮肤-神经免疫网络调节新的机制。
Objective:To explore local action of immunological regulation by moxibusion in hypoimmunity and immunologic derangement animal model.
Methods:(1)In the first part of our study,we used subac senescent rat model made by D-galactose injection as hypoimmunity subjects. After moxibustion on points from BL13 to BL23 of the Foot bladder meridian, we measured the content of serumal cortisol(CS) and the expresstion of major histocompatibility complex II(MHC-Ⅱ), Interleukin 12(IL-12), CD80, vimentin in local skin; (2) In the second part,we used adjunctive arthritis(AA) model made by Ferund's complete adjuvant(FCA) injection as immunologic derangemen subjects. After moxibusion on point ST36, we measured the changes of voix pedis' swelling and tumor necrosis factor alpha(TNF-α), IL-1β, IL-10 in serum to evaluate immunologic derangemen immunologic derangemen. Meanwhile, we also examine the expression of leptin and leptin acceptor in the partial skin of moxibustion, spleen, thoracic gland, hypothalamus and the content of leptin in serum to uncover the mechanism.
Results:(1)The content of CS in model group is higher than that in control group with significant statistical differences(p< 0.01);While the content of CS in moxa group is lower than that in model group(p< 0.01). For the expression of MHC-II, IL-12, CD-80, vimentin in local skin, in model group, the numbers of positive cells are less and the expressional intensity is lower than those in control group(p< 0.01), but the numbers of positive cells in moxa group are more than those in model group(p< 0.01). (2) Compared with model group, voix pedis' swelling in moxa group got gradually better and better.At day 7, there was statistical difference between them (p<0.05) but significant difference come out at day 14 (p<0.01). As the content of TNF-αand IL-1β, they are more in model group than those in control group(p< 0.01). However, the content of IL-10 in model group is more markedly than that in control group, so do the moxa group(p< 0.01). For changes of leptin and leptin receptor in ST36, the numbers of positive cells and the expression in model group are less than those in control group (p< 0.01), while the numbers of positive cells in moxa group are more than that in control group. In addition, the intensity of expression of leptin and leptin receptor in ST36 in moxa group is higher than that of control group(p< 0.01). The lepten content of serum in model group is higher markedly than that in control group(p< 0.01); the leptin content in serum in moxa group is higher than that in control group(p< 0.05). For the numbers of positive cells and the expression of lepten and leptin receptor, there are no statistical significance in spleen and thoracic gland between model and control group(P>0.05); so do the moxa group. However, for leptin and leptin receptor in hypothalamus, the numbers of positive cells in model group have statistical significance compared to control group(p<0.01), the expression in model group is higher than that in control group(p<0.01), the numbers of positive cells in moxa group are more than that in model group of lepten and leptin receptor in hypothalamus, p<0.01, the expression in moxa group is stronger than that inmodel group of lepten and leptin receptor in hypothalamus, p<0.05.
Conclusions:(1)Moxibustion may be activiate the expression of MHC-Ⅱ, IL-12, CD-80, vimentin in local skin to rectify hypoimmunity. (2) Moxibus-tion could enhance the expression of lepten and leptin receptor to adjust immunologic derangemen in AA model. (3) NICS,which is composed of local immune and neural immune system, would be a novel regulation tagert for moxibustion.
方法：(1)采用D-半乳糖注射形成的亚急性衰老模型为艾灸免疫低下调节载体,给予背部膀胱经肺俞-肾俞施灸,检测血清皮质酮含量及施灸部位皮肤MHC-Ⅱ、IL-12、CD-80、波形蛋白的表达；(2)采用完全弗氏佐剂注射造模佐剂性关节炎为免疫紊乱研究载体,给予艾灸“足三里”,以足跖肿胀改善、血清TNF-α、IL-1β、IL-10变化为艾灸免疫紊乱调节指标,并同时检测艾灸局部、脾脏、胸腺、下丘脑瘦素及瘦素受体表达和血清瘦素含量变化。结果：(1)D-半乳糖造模形成的衰老模型大鼠血清皮质酮含量高于对照组,差异具有统计学意义,p<0.01；艾灸组血清皮质酮含量低于模型组,p<0.01。模型组皮肤MHC-Ⅱ、IL-12、CD80、波形蛋白表达阳性细胞数少于空白组,表达强度也低于空白组,p<0.01；艾灸组施灸部位皮肤MHC-Ⅱ、IL-12、CD80、波形蛋白表达阳性细胞数多于模型组,表达强度也高于空白组,p<0.01。(2)艾灸组足跖肿胀程度从开始接受治疗后一直呈逐步下降趋势,在第7天与模型组相比,有显著差异(p<0.05),到第14天时,差异更为显著(p<0.01)。模型组TNF-α、IL-1β含量显著高于对照组,p<0.01；艾灸组的TNF-α、IL-1β含量显著低于对照组,p<0.01。模型组IL-10含量显著高于对照组,p<0.01；艾灸组的工L-10含量也显著高于对照组,p<0.01。模型组穴位局部瘦素、瘦素受体表达阳性细胞数少于空白组,表达强度也低于空白组,p<0.01;艾灸组穴位局部皮肤瘦素、瘦素受体表达阳性细胞数多于模型组,表达强度也高于空白组,p<0.01。模型组血清瘦素含量显著低于对照组,p<0.01；艾灸组血清瘦素含量显著高于对照组,p<0.05。模型组大鼠脾脏、胸腺瘦素、瘦素受体表达阳性细胞数、表达强度与空白组比较,差异没有统计学意义,P>0.05；艾灸组脾脏、胸腺瘦素、瘦素受体表达阳性细胞数、表达强度与模型组比较,差异也没有统计学意义,p>0.05。模型组大鼠下丘脑瘦素、瘦素受体表达阳性细胞数多于对照组,p<0.01,表达强度也高于空白组,p<0.01；艾灸组下丘脑瘦素、瘦素受体表达阳性细胞数多于模型组,P<0.01,表达强度也高于模型组,p<0.05。
结论：(1)艾灸可纠正衰老低下的免疫状态,可能与艾灸施术部位的MHC-Ⅱ、IL-12、CD80及波形蛋白的皮肤免疫激活有关；(2)艾灸可调整佐剂性关节炎模型紊乱的免疫功能,可能与下丘脑和穴位局部的瘦素、瘦素受体的表达增强有关；(3)艾灸对免疫调节的局部作用机制可能与神经免疫网络一起,形成艾灸调节免疫的皮肤-神经免疫网络调节新的机制。
Objective:To explore local action of immunological regulation by moxibusion in hypoimmunity and immunologic derangement animal model.
Methods:(1)In the first part of our study,we used subac senescent rat model made by D-galactose injection as hypoimmunity subjects. After moxibustion on points from BL13 to BL23 of the Foot bladder meridian, we measured the content of serumal cortisol(CS) and the expresstion of major histocompatibility complex II(MHC-Ⅱ), Interleukin 12(IL-12), CD80, vimentin in local skin; (2) In the second part,we used adjunctive arthritis(AA) model made by Ferund's complete adjuvant(FCA) injection as immunologic derangemen subjects. After moxibusion on point ST36, we measured the changes of voix pedis' swelling and tumor necrosis factor alpha(TNF-α), IL-1β, IL-10 in serum to evaluate immunologic derangemen immunologic derangemen. Meanwhile, we also examine the expression of leptin and leptin acceptor in the partial skin of moxibustion, spleen, thoracic gland, hypothalamus and the content of leptin in serum to uncover the mechanism.
Results:(1)The content of CS in model group is higher than that in control group with significant statistical differences(p< 0.01);While the content of CS in moxa group is lower than that in model group(p< 0.01). For the expression of MHC-II, IL-12, CD-80, vimentin in local skin, in model group, the numbers of positive cells are less and the expressional intensity is lower than those in control group(p< 0.01), but the numbers of positive cells in moxa group are more than those in model group(p< 0.01). (2) Compared with model group, voix pedis' swelling in moxa group got gradually better and better.At day 7, there was statistical difference between them (p<0.05) but significant difference come out at day 14 (p<0.01). As the content of TNF-αand IL-1β, they are more in model group than those in control group(p< 0.01). However, the content of IL-10 in model group is more markedly than that in control group, so do the moxa group(p< 0.01). For changes of leptin and leptin receptor in ST36, the numbers of positive cells and the expression in model group are less than those in control group (p< 0.01), while the numbers of positive cells in moxa group are more than that in control group. In addition, the intensity of expression of leptin and leptin receptor in ST36 in moxa group is higher than that of control group(p< 0.01). The lepten content of serum in model group is higher markedly than that in control group(p< 0.01); the leptin content in serum in moxa group is higher than that in control group(p< 0.05). For the numbers of positive cells and the expression of lepten and leptin receptor, there are no statistical significance in spleen and thoracic gland between model and control group(P>0.05); so do the moxa group. However, for leptin and leptin receptor in hypothalamus, the numbers of positive cells in model group have statistical significance compared to control group(p<0.01), the expression in model group is higher than that in control group(p<0.01), the numbers of positive cells in moxa group are more than that in model group of lepten and leptin receptor in hypothalamus, p<0.01, the expression in moxa group is stronger than that inmodel group of lepten and leptin receptor in hypothalamus, p<0.05.
Conclusions:(1)Moxibustion may be activiate the expression of MHC-Ⅱ, IL-12, CD-80, vimentin in local skin to rectify hypoimmunity. (2) Moxibus-tion could enhance the expression of lepten and leptin receptor to adjust immunologic derangemen in AA model. (3) NICS,which is composed of local immune and neural immune system, would be a novel regulation tagert for moxibustion.
引文
1. Bos J D. The skin as arI organ of immunity[J]. Clin Exp lmmunol,1997, 107(Suppl 1):3-5.
2. Dirk Roosterman, Tobias Goerge. Neuronal Control of Skin Function:The Skin as a Neuroimmunoendocrine Organ[J]. Physiol Rev,2006; 86:309-1379.
3. Dirk Roosterman, Tobias Goerge, Stefan W. Schneider, et al. Neuronal Control of Skin Function:The Skin as a Neuroimmunoendocrine Organ. Physiol. Rev.2006; 86:1309-1379.
4. Advenier C and Devillier P. Neurokinins and the skin. Allerg Immunol,1993;25: 280-282,285.
5. Andrzej S, Jacobo W. Neuroendocrinology of the Skin (J).Endocr Rev,2000, 21 (5):457-487.
6. Burkhard Poeggeler, Carla Schulz, Miguel A. Pappolla, et al. Leptin and the skin: a new frontier. Experimental Dermatology 2010; 19:12-18.
7.徐叔云,卞如濂,陈修主编.药理实验方法学(第三版),北京：人民卫生出版社,2002,1465.
8.徐叔云主编.药理实验方法学.北京：人民卫生出版社,1985；532
9.张传英,唐照亮.艾灸调节机体免疫功能研究概况,安徽中医学院学报.2009,28(2)：60-62
10.马本绪,崇桂琴.艾灸对机体免疫调节作用概述,江苏中医药.2008,40(1)：86-87
11.韩蔚伟,卢静,王大兵.衰老与免疫功能的变化,中国医学检验杂志.2008,9(3)：178-180
12. Allman, D., and Miller, J.P. (2005). B cell development and receptor diversity during aging. Curr. Opin. Immunol.17,463-467.
13. R. Hodes. Aging and the immune system.Current Opinion in Immunology,2005;17(5):455-456
14. Franceschi, C., Cossarizza, A. (1995). Introduction:The reshapingof the immune system with age. Int. Rev. Immunol.12,1-4.
15. Frasca, D., Riley, R.L., Blomberg, B.B. (2005). Humoral immuneresponse and B-cell functions including immunoglobulin class switch are downregulated in aged mice and humans. Semin. Immunol.17,378-384.
16. Linton, P.J., and Dorshkind, K. (2004). Age-related changes in lymphocyte development and function. Nat. Immunol.5,133-139.
17. Boraschi D, et al. Ageing and immunity. Addressing immune senescence to ensure healthy ageing. Vaccine(2010), doi:10.1016/j. vaccine.2010.03.035
18.崔美芝,刘浩,李春艳.衰老动物模型的建立及评价[J].中国比较医学杂志,2006,16(2)：118-121.
19.董晓华,张丹参,武海霞.衰老动物模型的研究及评价[J].河北北方学院学报,2004,21(6)：41-43.
20.幸浩洋,胡新珉,刘鸿莲,等.03衰老小鼠模型的DNA损伤研究[J].华西医科大学学报,2001,32(2)：229-231
21. akeda T. Senescence accelerated mouse (SAM):a biogerontological resource in aging research[J]. Neurobiol Aging,1999,20 (2):105-110
22.赵彩红.小鼠自然衰老模型的血脂水平及抗氧化能力的评价[J].医学理论与实践,2007,20(7)：745-746.
23.尹彤,徐斌,朱庆磊,等.自然衰老与半乳糖催老小鼠重要脏器的形态学差异[J].中国临床康复,2004,8(36)：8248-8249.
24.杨晨,海春旭,徐文,等.D-半乳糖致亚急性衰老小鼠模型肝mtDNA的改变[J].第四军医大学学报,2005,26(9)：812-815.
25.孙晓芳,王怀颖,户志杰,等.D-半乳糖致衰老小鼠肝肾睾丸组织氧化和抗氧化能力的变化[J].河北职工医学院学报,2004,21(1)：3-4.
26.王怀颖,张玮,石少慧,等.D-半乳糖老化模型小鼠抗氧化能力的实验研究[J].军医进修学院学报,2005,26(5)：397-398.
27. Osorio FG, Obaya AJ, Lopez-Otin C,et al. Accelerated ageing:from mechanism to therapy through animal models.Transgenic Res.2009 Feb;18(1):7-15
28.张进玉主编.类风湿关节炎.北京：人民卫生出版社,1987：524-528
29. Chyun YS, et al. Prostaglandins,1984; 27(1):97
30. Lewis AJ, et al. Pharmacology of inflammation. Amsterdam:Elsevier Science Puli,1985;376-8
31. Roberts BV. In:Dick WC, et al, eds. Recent advance in rheumatology. Vol 3. New York:Pitman,1983; 73-98
32. Zimmerman GA, Weyrich AS.Immunology. Arsonists in rheumatoid arthritis.Science.2010;327(5965):528-9.
33. Scrivo R, Di Franco M, Spadaro A, et al.The immunology of rheumatoid arthritis.Ann N Y Acad Sci.2007; 1108:312-22.
34. Valesini G, Barone F, Bompane D,et al.Advances in immunology and rheumatoid arthritis pathogenesis. Reumatismo.2004;56(1Suppl 1):9-20.
35.余曙光,郝亮,宋开源,等.艾灸对类风湿关节炎大鼠血清ICAM-1的影响.中国针灸,2002,22(10).690-692
36.刘旭光,黄迪君,郝亮,等.艾灸对类风湿性关节炎大鼠下丘脑-垂体-肾上腺皮质轴的影响[J].中国中医基础医学杂志,2003,9(2)：137-139.
37.陈晓莉,黄迪君,郝亮等.麦粒灸对类风湿关节炎大鼠TNF-β, IFN-γ的影响.针刺研究,2002：27(3)：201-204
38.黄迪君,骆永珍,周志昆,等.灸刺对实验性类风湿性关节炎大鼠红细胞免疫功能和血浆皮质醇影响的观察.中国针灸.1995;6：25-28
39.黄迪君,韩哲林,罗荣等.麦粒灸对实验性RA大鼠足跖肿胀度及滑膜组织Caspase-3表达的影响.成都中医药大学学报2003 26(2)：29-30
40.迪君,韩哲林,罗荣等.麦粒灸对佐剂性关节炎大鼠足跖肿胀度及滑膜组织NF-kB表达的影响.上海针灸杂志.2003,22(3)：9-11
41.陈晓莉,黄迪君等.麦粒灸对佐剂性关节炎大鼠细胞免疫功能的影响.上海针灸杂志.2003,22(1)：14-16.
42.黄迪君,余曙光,韩哲林,等.麦粒灸对实验性RA大鼠局部组织炎症介质的影响.上海针灸杂志.2002,8(4)：443-44
43.郝亮.艾灸对实验性RA大鼠的神经免疫内分泌网络调控机制.成都中医药大 学博士学位论文；2001
44.罗荣.交感神经在艾灸治疗实验性RA中的作用机理研究.成都中医药大学博士学位论文；2002
45.马珠红,等·针灸对类风湿性关节患者免疫—神经—内分泌系统影响的临床研究·中国针灸,1997；(9)：529-531
46.王绪辉.肢体痹证的造模方法.上海中医药杂志,1986；3：3
47.王绪辉.风寒湿性关节痛实验模型及病理学研究.中医杂志,1990；2：52
48.吕爱华主编.类风湿关节炎中西医结合应用基础研究.北京：中医古籍出版社,1999：23-32
49.张进玉主编.类风湿关节炎.北京：人民卫生出版社,1987：524-528
50. Chyun YS, et al. Prostaglandins,1984; 27(1):97
51.马东来.大鼠佐剂性关节炎的诱导及其免疫异常研究.中国实验临床免疫学杂志,1995；7(3)：13-7
52. Lewis AJ, et al. Pharmacology of inflammation. Amsterdam:Elsevier Science Puli,1985;376-8
53. Roberts BV. In:Dick WC, et al, eds. Recent advance in rheumatology. Vol 3. New York:Pitman,1983; 73-98
54.杜莅娜,姜建伟, 吴根诚等.纳洛酮和电针改善创伤应激大鼠的免疫功能.生理学报,1998：50(6)：636-642
55.赵蓉,马春红,谭连红等.针刺对免疫抑制大鼠巨噬细胞功能的影响.针刺研究,1994；19(2)：66-68
56.李建萍,张洪度,宫斌.针刺大鼠足三里对糖皮质素及免疫的影响.上海针灸杂志,1994；13(6)：281
57.杨金洪, 赵蓉, 袁纪阁等.针刺防治化疗副反应的实验研究：不同穴位的针刺效应比较.针刺研究,1994：19(1)：75-78
58. Bos JD, Kapsenberg ML. The skin immune system (SIS):its cellular constituents and their interactions. Immunol Today 1986; 7:235-40.
59. Nickoloff BJ. Dermal Immune System. Boca Raton:CRC Press,1993;
60. Bos JD. Skin Immune System (SIS). In:Bos JD(Ed.) Skin Immune System (SIS): Cutaneous Immunology and Clinical Immunodermatology. CRC Press, Boca Raton,2005:3-17
61. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease.Nat Rev Immunol.2009;9(10):679-91
62. Dirk Roosterman, Tobias Goerge, Stefan W.et al.Neuronal Control of Skin Function:The Skin as a Neuroimmunoendocrine Organ. Physiol. Rev.2006; 86: 1309-1379.
63.曹序茂.免疫功能与衰老[J].解放军健康,2000,(3)：20-21.
64. Ogra PL. Ageing and its possible impact on mucosal immune responses. Ageing ResRev.2010;9(2):101-6.
65. Nigam Y, Knight J.Exploring the anatomy and physiology of ageing. Part 9--The immune system.Nurs Times.2008;104(47):58-9
66. Herman WA, Lacka K.Pol Ageing and immune system Arch Med Wewn. 2004;112(6):1487-96.
67. Bauer ME. Stress, glucocorticoids and ageing of the immune system.Stress. 2005;8(1):69-83.
68. Wilder RL, et al. Neuroendocrine hormonal factors in rheumatoid arthritis and related conditions. Curr Opin Rheumatol,1990; 2(3):436-40
69. Harkness JA, et al. Circadian variation in disease activity in rheumatoid arthritis. Br Med J,1982(6315); 284:551-4
70. Neeck G, et al. Adrenal secretion of cortisol in patients with rheumatoid arthritis. J Rheumatol,1990; 17(1):24-9
71. Hall J, et al. Abnormal hypothalamic-pituitary-adrenal axis function in rheumatoid arthritis. Effects of nonsteroidal antiinflammatory drugs and water immersion. Arthritis Rheum,1994; 37(8):1132-7
72. Jorgensen C, et al. Dysregulation of the hypothalamo-pituitary axis in rheumatoid arthritis. J Rheumatol,1995; 22(10):1829-33
73. Baerwald CG, et al. Neurohumoral mechanisms in rheumatoid arthritis. Scand J Rheumatol,1997; 26(1):1-3
74. Gudbjornsson B, et al. Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis. Effect of glucocorticoids J Rheumatol,1996; 23(4):596-602
75. Jorundsson E, Press CM, Landsverk T. Distribution of MHC-Ⅱ and CD1 molecules in the skin of lambs and changes during experimentally-induced contact hypersensitivity.Vet Immunol Immunopathol.2000;74(1-2):87-101.
76. Gelin C, Sloma I, Charron D, et al. Regulation of MHC Ⅱ and CD1 antigen presentation:from ubiquity to security.J Leukoc Biol.2009;85(2):215-24
77. Melian A, Beckman EM, Porcelli SA, et al. Antigen presentation by CD1 and MHC-encoded class Ⅰ-like molecules.Curr Opin Immunol.1996;8(1):82-8.
78. Zabka TS, Romano TA. Distribution of MHC Ⅱ (+) cells in skin of the Atlantic bottlenose dolphin (Tursiops truncatus):an initial investigation of dolphin dendritic cells.Anat Rec A Discov Mol Cell Evol Biol.2003;273(1):636-47.
79. Cocco C, Pistoia V, Airoldi I.New perspectives for melanoma immunotherapy: role of IL-12.Curr Mol Med.20099(4):459-69.
80. Meeran SM, Katiyar N, Singh T, et al.Loss of endogenous interleukin-12 activates survival signals in ultraviolet-exposed mouse skin and skin tumors.Neoplasia. 2009;11(9):846-55.
81. Katiyar SK. Interleukin-12 and photocarcinogenesis.Toxicol Appl Pharmacol. 2007;224(3):220-7.
82. SelvakarAt et aL. lnmmnogetic,1992; 36:175
83.BordelloF et al.J Inmmnol·1994; 153:5038
84. Van de Ven R, Lindenberg JJ, Oosterhoff D, et al. Selective transduction of mature DC in human skin and lymph nodes by CD80/CD86-targeted fiber-modified adenovirus-5/3. J Immunother.2009;32(9):895-906.
85. Byrne SN, Halliday GM. High levels of Fas ligand and MHC class Ⅱ in the absence of CD80 or CD86 expression and a decreased CD4+ T cell Infiltration,enables murine skin tumours to progress. Cancer Immunol Immunother.2003;52(6):396-402.
86. Ossevoort MA, Lorre K, Boon L, et al. Prolonged skin graft survival by administration of anti-CD80 monoclonal antibody with cyclosporin A. J Immunother.1999;22(5):381-9.
87. Williams IR, Ort RJ, Daley D, et al.Constitutive expression of B7-1 (CD80) on mouse keratinocytes does not prevent development of chemically induced skin papillomas and carcinomas. J Immunol.1996;156(9):3382-8.
88. Mitra RS, Judge TA, Nestle FO, et al. Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7-1 (CD8o) and B7-2 (CD86) expression. J Immunol.1995;154(6):2668-77.
89. Esteban MA, Rodriguez A, Ayala AG, et al. Effects of high doses of cortisol on innate cellular immune response of seabream (Sparus aurata L.).Gen Comp Endocrinol.2004;137(1):89-98.
90. Kueper T, Grune T, Muhr GM, et al.Modification of vimentin:a general mechanism of nonenzymatic glycation in human skin. Ann N Y Acad Sci. 2008;1126:328-32.
91. Kueper T, Grune T, Prahl S, et al. Vimentin is the specific target in skin glycation. Structural prerequisites,functional consequences, and role in skin aging. J Biol Chem.2007;282(32):23427-36.
92. Hashimoto M, Inoue S, Ogawa S, et al.Rapid fragmentation of vimentin in human skin fibroblasts exposed to tamoxifen:a possible involvement of caspase-3. Biochem Biophys Res Commun.1998;247(2):401-6.
93. Bavdek SV, Golob Z, van Dijk J, et al. Vimentin- and desmin-positive cells in the moulting budgerigar (Melopsittacus undulatus) skin. Anat Histol Embryol. 1997;26(3):173-8.
94. Iyer PV, Leong AS. Poorly differentiated squamous cell carcinomas of the skin can express vimentin. J Cutan Pathol.1992;19(1):34-9.
95. Hosaka K, Ryu J, Saitoh S, et al. The combined effects of anti-TNFalpha antibody and IL-1 receptor antagonist in human rheumatoid arthritis synovial membrane.Cytokine.2005;32(6):263-9.
96. Raffeiner B, Botsios C, Ometto F,et al. TNFalpha blockers and infectious risk in rheumatoid arthritis.Reumatismo.2009;61(3):165-73.
97. Xu S, Lu H, Lin J, et al Regulation of TNFalpha and IL1beta in rheumatoid arthritis synovial fibroblasts by leukotriene B4. Rheumatol Int.2009. [Epub ahead of print] PubMed PMID:19809821.
98. Scrivo R, Conti F, Spinelli FR, et al. Switching between TNFalpha antagonists in rheumatoid arthritis:personal experience and review of the literature. Reumatismo. 2009;61(2):107-17.
99. Machado P, Santos A, Pereira C,et al.Increased prevalence of allergic sensitisation in rheumatoid arthritis patients treated with anti-TNFalpha. Joint Bone Spine. 2009;76(5):508-13.
100. Brocq O, Millasseau E, Albert C, et al.Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine.2009;76(4):350-5.
101. Kehlen A, Lauterbach R, Santos AN, et al. IL-1 beta- and IL-4-induced down-regulation of autotaxin mRNA and PC-1 in fibroblast-like synoviocytes of patients with rheumatoid arthritis (RA). Clin Exp Immunol.2001;123(1):147-54.
102. Punzi L, Pianon M, Bertazzolo N,et al.Interrelationship between synovial fluid interleukin (IL)-6, IL-1 beta and disease activity indices in rheumatoid arthritis. Rheumatol Int.1994;14(2):83-4.
103. Zangerle PF, De Groote D, Lopez M, et al. Direct stimulation of cytokines (IL-1 beta,TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood:Ⅱ. Application to rheumatoid arthritis and osteoarthritis. Cytokine. 1992;4(6):568-75.
104. Ruschen S, Lemm G, Warnatz H. Spontaneous and LPS-stimulated production of intracellular IL-1 beta by synovial macrophages in rheumatoid arthritis is inhibited by IFN-gamma. Clin Exp Immunol.1989;76(2):246-51.
105. Alanara T, Karstila K, Moilanen T, Set al. Expression of IL-10 family cytokines in rheumatoid arthritis:elevated levels of IL-19 in the joints. Scand J Rheumatol.2010;39(2):118-26.
106. Heo YJ, Joo YB, Oh HJ, et al. IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4+ T cell population of rheumatoid arthritis patients. Immunol Lett.2010;127(2):150-6.
107. Hussein MR, Fathi NA, El-Din AM, et al. Alterations of the CD4(+), CD8 (+) T cell subsets, interleukins-lbeta, IL-10, IL-17, tumor necrosis factor-alpha and soluble intercellular adhesion molecule-1 in rheumatoid arthritis and osteoarthritis: preliminary observations. Pathol Oncol Res.2008;14(3):321-8.
108. Mitchell A, Rentero C, Endoh Y, et al. LILRA5 is expressed by synovial tissue macrophages in rheumatoid arthritis, selectively induces pro-inflammatory cytokines and IL-10 and is regulated by TNF-alpha, IL-10 and IFN-gamma. Eur J Immunol.2008;38(12):3459-73.
109. Moreno OM, Gonzalez CI, Saaibi DL, et al.Polymorphisms of IL-10 gene promoter and rheumatoid arthritis in a Colombian population. Biomedica. 2007;27(1):56-65.
110. Litinsky I, Paran D, Levartovsky D, et al. The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. Cytokine.2006;33(2):106-10.
111. Miellot A, Zhu R, Diem S, et al. Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway. Eur J Immunol.2005;35(12):3704-13.
112. Yamana J, Yamamura M, Okamoto A, et al.Resistance to IL-10 inhibition of interferon gamma production and expression of suppressor of cytokine signaling 1 in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res Ther. 2004;6(6):R567-77.
113. Appel H, Neure L, Kuhne M, et al. An elevated level of IL-10- and TGFbeta-secreting T cells, B cells and macrophages in the synovial membrane of patients with reactive arthritis compared to rheumatoid arthritis.Clin Rheumatol. 200423(5):435-40.
114. Foey AD, Field S, Ahmed S, et al. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production:implications for rheumatoid arthritis. Arthritis Res Ther.2003;5(6):R317-28.
115. Bodman-Smith MD, Corrigall VM, Kemeny DM, et al. BiP, a putative autoantigen in rheumatoid arthritis, stimulates IL-10-producing CD8-positive T cells from normal individuals. Rheumatology (Oxford).2003;42(5):637-44.
116. Verhoef CM, van Roon JA, Vianen ME, et al. Interleukin 10(IL-10), not IL-4 or interferon-gamma production, correlates with progression of joint destruction in rheumatoid arthritis. J Rheumatol.2001;28(9):1960-6.
117. Eskdale J, McNicholl J, Wordsworth P, et al. Interleukin-10 microsatellite polymorphisms and IL-10 locus alleles in rheumatoid arthritis susceptibility. Lancet.1998;352(9136):1282-3.
118. Keystone E, Wherry J, Grint P. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am.1998;24(3):629-39.
119. Hajeer AH, Lazarus M, Turner D, et al. IL-10 gene promoter polymorphisms in rheumatoid arthritis. Scand J Rheumatol.1998;27(2):142-5.
120. Raziuddin S, Bahabri S, Al-Dalaan A, et al. A mixed Th1/Th2 cell cytokine response predominates in systemic onset juvenile rheumatoid arthritis: immunoregulatory IL-10 function. Clin Immunol Immunopathol. 1998;86(2):192-8.
121. Al-Janadi M, al-Dalaan A, al-Balla S, et al.Interleukin-10 (IL-10) secretion in systemic lupus erythematosus and rheumatoid arthritis:IL-10-dependent CD4+CD45RO+ T cell-B cell antibody synthesis. J Clin Immunol. 1996;16(4):198-207.
122. Bucht A, Larsson P, Weisbrot L, et al. Expression of interferon-gamma (IFN-gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA). Clin Exp Immunol.1996;103(3):357-67.
123. 杨慎峭,刘旭光,余曙光,等.艾灸对类风湿性关节炎家兔关节滑膜液IL-1β, TNF-α含量的影响.成都中医药大学学报.2005,28(3)：11-12
124. 杨慎峭,房繁恭,王海军,等.灸法治疗类风湿关节炎临床与实验研究述评.中医药学刊.2004,22(11)：2109-2110
125. 王磊,李学武等.艾灸疗法作用机理国内外研究进展.中国针灸.2001,21(9)：567-570
126. Villanueva EC, Myers MG Jr. Leptin receptor signaling and the regulation of mammalian physiology. Int J Obes (Lond).2008;32 Suppl 7:S8-12.
127. Tanaka T, Masuzaki H, Ebihara K, et al. Clinical and biological consequences of leptin receptor mutation]. Nippon Rinsho.2006;Suppl3:241-8.
128. Leshan RL, Bjornholm M, Munzberg H, et al. Leptin receptor signaling and action in the central nervous system. Obesity (Silver Spring).2006; 14 Suppl 5:208S-212S.
129. Ebihara K, Nakao K. Leptin gene and leptin receptor gene]. Nippon Rinsho.2006;64 Suppl 5:391-5.
130. Myers MG Jr. Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog Horm Res.2004;59:287-304.
131. Bates SH, Myers MG Jr. The role of leptin receptor signaling in feeding and neuroendocrine function. Trends Endocrinol Metab.2003;14(10):447-52.
132. Halle M, Persson PB. Role of leptin and leptin receptor in inflammation. Am J Physiol Regul Integr Comp Physiol.2003;284(3):R760-2.
133. Ogawa Y, Nakao K. Leptin and leptin receptor. Nippon Rinsho. 2002;60Suppl 7:571-6.
134. Heshka JT, Jones PJ. A role for dietary fat in leptin receptor, OB-Rb,function. Life Sci.2001;69(9):987-1003.
135. Nishimura H, Ogawa Y, Nakao K. Structures and functions of leptin and leptin receptor. Nippon Rinsho.2001;59 Suppl 2:509-14.
136. Targonska-Stepniak B, Dryglewska M, Majdan M. Adiponectin and leptin serum concentrations in patients with rheumatoid arthritis. Rheumatol Int. 2010;30(6):731-7.
137. Derdemezis CS, Filippatos TD, Voulgari PV, et al.Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis. Fundam Clin Pharmacol.2009;23(5):595-600.
138. Popa C, Netea MG, de Graaf J, et al.Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. J Rheumatol.2009;36(4):724-30.
139. Aguilar-Chavez EA, Gamez-Nava JI, Lopez-Olivo MA, et al. Circulating leptin and bone mineral density in rheumatoid arthritis. J Rheumatol. 2009;36(3):512-6.
140. Seven A, Guzel S, Aslan M, et al. Serum and synovial fluid leptin levels and markers of inflammation in rheumatoid arthritis. Rheumatol Int. 2009;29(7):743-7.
141. Targonska-Stepniak B, Majdan M, Dryglewska M. Leptin serum levels in rheumatoid arthritis patients:relation to disease duration and activity. Rheumatol Int.2008;28(6):585-91.
142. Wislowska M, Rok M, Jaszczyk B, et al. Serum leptin in rheumatoid arthritis. Rheumatol Int.2007;27(10):947-54.
143. Lee SW, Park MC, Park YB, et al. Measurement of the serum leptin level could assist disease activity monitoring in rheumatoid arthritis. Rheumatol Int. 2007;27(6):537-40.
144. Hizmetli S, Kisa M, Gokalp N, et al. Are plasma and synovial fluid leptin levels correlated with disease activity in rheumatoid arthritis? Rheumatol Int. 2007;27(4):335-8.
145. Gunaydin R, Kaya T, Atay A, et al. Serum leptin levels in rheumatoid arthritis and relationship with disease activity. South Med J.2006;99(10):1078-83.
146. Salazar-Paramo M, Gonzalez-Ortiz M, Gonzalez-Lopez L, et al. Serum leptin levels in patients with rheumatoid arthritis. J Clin Rheumatol.2001;7(1):57-9.
147. Toussirot E, Nguyen NU, Dumoulin G, et al. Relationship between growth hormone-IGF-I-IGFBP-3 axis and serum leptin levels with bone mass and body composition in patients with rheumatoid arthritis.Rheumatology (Oxford). 2005;44(1):120-5.
148. Harle P, Pongratz G, Weidler C, et al. Possible role of leptin in hypoandrogenicity in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis.2004;63(7):809-16.
149. Bokarewa M, Bokarew D, Hultgren O, et al. Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62(10):952-6.
150. Fraser DA, Thoen J, Bondhus S, et al. Reduction in serum leptin and IGF-1 but preserved T-lymphocyte numbers and activation after a ketogenic diet in rheumatoid arthritis patients.Clin Exp Rheumatol.2000;18(2):209-14.
151. 陈啸峰.电针治疗单纯性肥胖及对血清瘦素和胰岛素影响的研究.针灸临床杂志.2009,25(8)：3-5
152. 王澍欣,李艳慧.穴位埋线对肥胖模型大鼠瘦素水平及血脂的影响.天津中医药.2009,26(1)：63-65
153. 钟国存.针灸治疗单纯性肥胖临床及机理研究进展.山西中医学院学报.2007,8(5)：55-57
154. 刘敏,陆亚康,戴利成等.针药并用治疗单纯性肥胖的临床研究.中国中医药科技.2009(3)：169-170
155. 龚美蓉,徐斌,毛珍等.针刺对肥胖模型大鼠下丘脑瘦素受体mRNA的表达与针刺的影响.中国组织工程研究与临床康复.2008,12(46)：9105-9108
156. 李建武,刘建民,熊源胤等.针灸对类风湿性关节炎神经-内分泌-免疫网络调节作用的研究进展.中医研究.2006,19(3)：57-60
157. 施茵,周珊玲.足三里穴对神经—内分泌—免疫网络的调节作用.江西中医学院学报.2003,15(2)：37-39
158. 刘心莲,尹淑英针灸对类风湿性关节炎患者免疫—神经—内分泌系统影响的临床研究.中国针灸.1997,17(9)：529-531.
159. 李辉,李晓泓.神经肽对针灸免疫调节影响的研究进展.上海针灸杂志.2003,22(3)：41-44
160.唐照亮,余新欢等.6—羟色多巴胺化学损毁小鼠外周交感神经对艾灸免疫调节作用的影响.针刺研究.2001,26(4)：299-302.
1.杨力强,李晓红,邓柏颖.化脓灸对感冒易感患者T细胞亚群影响的研究[J].新中医,2008,40(9)：74-75
2.吴炳煌,吴明霞,林宏等.隔姜灸神阚治疗支气管哮喘疗效与T细胞亚群含量变化关系的分析[J].中国针灸,1997,17(7)：389
3.王松梅,李兴国,张立群.神阙隔药灸疗法治疗溃疡性结肠炎的临床观察[J].中国针灸,2006,26(2)：97-99
4.鞠琰莉,王黎,刘金芝等.电针、艾灸、埋线对痛经大鼠T细胞亚群水平的影响[J].上海针灸杂志,2007,26(9)：43-46
5.曹毅,马泽云,郭平.艾灸阿是穴对多发性跖疣患者细胞免疫功能的调节作用[J].浙江中医学院学报,2004,28(4)：64
6.袁民,傅莉萍,陈雪华等.艾灸对荷瘤小鼠免疫功能的影响[J].针刺研究,2003,28(2)：11
7.成拯,姜翼,陈凯.放化疗法配合艾灸神阙穴治疗晚期鼻咽癌42例近期疗效观察[J].新中医,2005,37(4)：58-59
8.周立华,卢依平.从艾灸治疗艾滋病腹泻看艾灸治艾优势[J].河南中医学院学报,2005,20(3)：4-5
9.徐兰凤,喻志冲,沈梅红.艾灸对60例食道癌放疗患者免疫功能的影响[J].2008,24(1)：12-14
10.邓宏,龙顺钦,吴万垠等.艾灸防治化疗致白细胞减少症46例疗效观察[J].新中医,2007,39(6)：90-92
11.郑雪峰,聂焱,王志强.艾灸关元穴对化疗后低白细胞模型大鼠外周血象影响的实验研究[J].湖北中医杂志,2009,31(5)：5-6
12.崔瑾,严洁.艾灸或针刺膈俞穴对环磷酰胺致白细胞减少大鼠诱生粒细胞一巨噬细胞集落刺激因子的作用[J].中国组织工程研究与临床康复,2007,11(28)：5473-5476
13.张帆,林周杰,黄镜招.灸治关元穴对阳虚患者不同时辰红细胞免疫功能影响[J].医学信息,2009；1(8)：7-8
14.沈梅红,徐兰凤,詹臻等.艾灸对放疗宫颈癌患者的红细胞免疫粘附功能和TNF的影响[J].安徽中医临床杂志,2002,14(5)：352-353
15.钱卫华.针刺五脏夹脊穴对红细胞免疫功能影响的实验研究[J].针灸临床杂志,1995,11(5)：30-33
16.宋小鸽,唐照亮,侯正明.艾灸对吗啡戒断小鼠红细胞免疫功能的调节作用[J].针刺研究,2000,6(9)：51-53
17.田华张,陈俊玲.艾灸强壮穴对慢性疲劳综合征患者免疫功能的影响[J].深圳中西医结合杂志,2006,16(4)：225-226
18.居贤水,赵粹英.艾灸延缓衰老的临床观察[J].上海针灸杂志,1995,3：22-23
19.邱幸生,陈凯,佟丽.灸神阙穴对移植瘤小鼠血清白细胞介素12及NK细胞活性的影响[J].中医杂志,2003,44(3)：186-187
20.宋小鸽,唐照亮,金敖兴等.艾灸对吗啡依赖小鼠细胞免疫功能的影响[J].针刺研究,1999,24(4)：29
21.邢红梅,祝佩芹,李建茹.健脾补肾中药配合穴位艾灸治疗卵巢早衰的临床研究[J].新中医,2007,39(4)：26-27
22.虞永志.艾灸对宫颈癌放疗患者免疫球蛋白的影响[J].中毕现代中西医杂志,2003,8(1)：719-720
23.喻志冲,徐兰风,詹臻.艾灸对宫颈癌放疗患者免疫球蛋白的影响[J].上海针灸杂志,2002,21(6)：15-16
24.吴焕淦,王景辉,陈汉平等.隔药灸治疗肠易激综合征的疗效与免疫学机理初探[J].中国针灸,1996,2：43
25.李红,朱梅菊,高顺生.针灸足三里穴对小鼠运动能力及部分免疫指标的影响[J].中国运动医学杂志,2004,23(1)：42-45
26.邓柏颖,杨力强,罗敏然.化脓灸提高“体虚易感”患者免疫力的临床研究[J].四川中医,2005,23(1)：86-87
27.高希言,封丽华,李卫红等.艾灸督脉穴对亚急性衰老小鼠自由基与免疫器官的影响[J].河南中医学院学报,2003,18(5)：22
28.黄哗,尚明华.艾灸足三里穴对腹泻小鼠脾,胸腺重量的影响[J].山西中医,1997,13(5)：41-42
29.吴娟,胥志斌,占国.化脓灸对免疫性慢性肝损伤小鼠免疫功能的影响[J].中医药管理杂志,2007,15(4)：283-285
30.周鹏,赵仓焕.浅谈灸法在“治未病”中的应用[J].时珍国医国药,2006, 17(5)：865-866
31.王慧.逆灸应激法预防传染性非典型肺炎初探[J].中医研究,2003,16(5)： 52
32.高树中.隔药灸脐法延缓衰老临床观察[J].中国针灸,2007,27(6)：398
33.李晓泓.逆灸关元穴对自然更年期大鼠下丘脑雌激素受体a和促肾E腺激素释放激素及血浆促肾上腺激素的调节[J].中国临床康复,2006,10(7)：118
34.李晓泓.逆灸关元穴对不同月龄更年期大鼠肿瘤坏死因子a及脾脏雌激素受体a的影响[J].中国临床康复,2006,10(43)：171
35.李晓泓.逆灸对自然更年期大鼠子宫组织形态及EZ,P和ER-a影响的实验研究[J].北京中医药大学学报,2006,29(8)：558
2. Dirk Roosterman, Tobias Goerge. Neuronal Control of Skin Function:The Skin as a Neuroimmunoendocrine Organ[J]. Physiol Rev,2006; 86:309-1379.
3. Dirk Roosterman, Tobias Goerge, Stefan W. Schneider, et al. Neuronal Control of Skin Function:The Skin as a Neuroimmunoendocrine Organ. Physiol. Rev.2006; 86:1309-1379.
4. Advenier C and Devillier P. Neurokinins and the skin. Allerg Immunol,1993;25: 280-282,285.
5. Andrzej S, Jacobo W. Neuroendocrinology of the Skin (J).Endocr Rev,2000, 21 (5):457-487.
6. Burkhard Poeggeler, Carla Schulz, Miguel A. Pappolla, et al. Leptin and the skin: a new frontier. Experimental Dermatology 2010; 19:12-18.
7.徐叔云,卞如濂,陈修主编.药理实验方法学(第三版),北京：人民卫生出版社,2002,1465.
8.徐叔云主编.药理实验方法学.北京：人民卫生出版社,1985；532
9.张传英,唐照亮.艾灸调节机体免疫功能研究概况,安徽中医学院学报.2009,28(2)：60-62
10.马本绪,崇桂琴.艾灸对机体免疫调节作用概述,江苏中医药.2008,40(1)：86-87
11.韩蔚伟,卢静,王大兵.衰老与免疫功能的变化,中国医学检验杂志.2008,9(3)：178-180
12. Allman, D., and Miller, J.P. (2005). B cell development and receptor diversity during aging. Curr. Opin. Immunol.17,463-467.
13. R. Hodes. Aging and the immune system.Current Opinion in Immunology,2005;17(5):455-456
14. Franceschi, C., Cossarizza, A. (1995). Introduction:The reshapingof the immune system with age. Int. Rev. Immunol.12,1-4.
15. Frasca, D., Riley, R.L., Blomberg, B.B. (2005). Humoral immuneresponse and B-cell functions including immunoglobulin class switch are downregulated in aged mice and humans. Semin. Immunol.17,378-384.
16. Linton, P.J., and Dorshkind, K. (2004). Age-related changes in lymphocyte development and function. Nat. Immunol.5,133-139.
17. Boraschi D, et al. Ageing and immunity. Addressing immune senescence to ensure healthy ageing. Vaccine(2010), doi:10.1016/j. vaccine.2010.03.035
18.崔美芝,刘浩,李春艳.衰老动物模型的建立及评价[J].中国比较医学杂志,2006,16(2)：118-121.
19.董晓华,张丹参,武海霞.衰老动物模型的研究及评价[J].河北北方学院学报,2004,21(6)：41-43.
20.幸浩洋,胡新珉,刘鸿莲,等.03衰老小鼠模型的DNA损伤研究[J].华西医科大学学报,2001,32(2)：229-231
21. akeda T. Senescence accelerated mouse (SAM):a biogerontological resource in aging research[J]. Neurobiol Aging,1999,20 (2):105-110
22.赵彩红.小鼠自然衰老模型的血脂水平及抗氧化能力的评价[J].医学理论与实践,2007,20(7)：745-746.
23.尹彤,徐斌,朱庆磊,等.自然衰老与半乳糖催老小鼠重要脏器的形态学差异[J].中国临床康复,2004,8(36)：8248-8249.
24.杨晨,海春旭,徐文,等.D-半乳糖致亚急性衰老小鼠模型肝mtDNA的改变[J].第四军医大学学报,2005,26(9)：812-815.
25.孙晓芳,王怀颖,户志杰,等.D-半乳糖致衰老小鼠肝肾睾丸组织氧化和抗氧化能力的变化[J].河北职工医学院学报,2004,21(1)：3-4.
26.王怀颖,张玮,石少慧,等.D-半乳糖老化模型小鼠抗氧化能力的实验研究[J].军医进修学院学报,2005,26(5)：397-398.
27. Osorio FG, Obaya AJ, Lopez-Otin C,et al. Accelerated ageing:from mechanism to therapy through animal models.Transgenic Res.2009 Feb;18(1):7-15
28.张进玉主编.类风湿关节炎.北京：人民卫生出版社,1987：524-528
29. Chyun YS, et al. Prostaglandins,1984; 27(1):97
30. Lewis AJ, et al. Pharmacology of inflammation. Amsterdam:Elsevier Science Puli,1985;376-8
31. Roberts BV. In:Dick WC, et al, eds. Recent advance in rheumatology. Vol 3. New York:Pitman,1983; 73-98
32. Zimmerman GA, Weyrich AS.Immunology. Arsonists in rheumatoid arthritis.Science.2010;327(5965):528-9.
33. Scrivo R, Di Franco M, Spadaro A, et al.The immunology of rheumatoid arthritis.Ann N Y Acad Sci.2007; 1108:312-22.
34. Valesini G, Barone F, Bompane D,et al.Advances in immunology and rheumatoid arthritis pathogenesis. Reumatismo.2004;56(1Suppl 1):9-20.
35.余曙光,郝亮,宋开源,等.艾灸对类风湿关节炎大鼠血清ICAM-1的影响.中国针灸,2002,22(10).690-692
36.刘旭光,黄迪君,郝亮,等.艾灸对类风湿性关节炎大鼠下丘脑-垂体-肾上腺皮质轴的影响[J].中国中医基础医学杂志,2003,9(2)：137-139.
37.陈晓莉,黄迪君,郝亮等.麦粒灸对类风湿关节炎大鼠TNF-β, IFN-γ的影响.针刺研究,2002：27(3)：201-204
38.黄迪君,骆永珍,周志昆,等.灸刺对实验性类风湿性关节炎大鼠红细胞免疫功能和血浆皮质醇影响的观察.中国针灸.1995;6：25-28
39.黄迪君,韩哲林,罗荣等.麦粒灸对实验性RA大鼠足跖肿胀度及滑膜组织Caspase-3表达的影响.成都中医药大学学报2003 26(2)：29-30
40.迪君,韩哲林,罗荣等.麦粒灸对佐剂性关节炎大鼠足跖肿胀度及滑膜组织NF-kB表达的影响.上海针灸杂志.2003,22(3)：9-11
41.陈晓莉,黄迪君等.麦粒灸对佐剂性关节炎大鼠细胞免疫功能的影响.上海针灸杂志.2003,22(1)：14-16.
42.黄迪君,余曙光,韩哲林,等.麦粒灸对实验性RA大鼠局部组织炎症介质的影响.上海针灸杂志.2002,8(4)：443-44
43.郝亮.艾灸对实验性RA大鼠的神经免疫内分泌网络调控机制.成都中医药大 学博士学位论文；2001
44.罗荣.交感神经在艾灸治疗实验性RA中的作用机理研究.成都中医药大学博士学位论文；2002
45.马珠红,等·针灸对类风湿性关节患者免疫—神经—内分泌系统影响的临床研究·中国针灸,1997；(9)：529-531
46.王绪辉.肢体痹证的造模方法.上海中医药杂志,1986；3：3
47.王绪辉.风寒湿性关节痛实验模型及病理学研究.中医杂志,1990；2：52
48.吕爱华主编.类风湿关节炎中西医结合应用基础研究.北京：中医古籍出版社,1999：23-32
49.张进玉主编.类风湿关节炎.北京：人民卫生出版社,1987：524-528
50. Chyun YS, et al. Prostaglandins,1984; 27(1):97
51.马东来.大鼠佐剂性关节炎的诱导及其免疫异常研究.中国实验临床免疫学杂志,1995；7(3)：13-7
52. Lewis AJ, et al. Pharmacology of inflammation. Amsterdam:Elsevier Science Puli,1985;376-8
53. Roberts BV. In:Dick WC, et al, eds. Recent advance in rheumatology. Vol 3. New York:Pitman,1983; 73-98
54.杜莅娜,姜建伟, 吴根诚等.纳洛酮和电针改善创伤应激大鼠的免疫功能.生理学报,1998：50(6)：636-642
55.赵蓉,马春红,谭连红等.针刺对免疫抑制大鼠巨噬细胞功能的影响.针刺研究,1994；19(2)：66-68
56.李建萍,张洪度,宫斌.针刺大鼠足三里对糖皮质素及免疫的影响.上海针灸杂志,1994；13(6)：281
57.杨金洪, 赵蓉, 袁纪阁等.针刺防治化疗副反应的实验研究：不同穴位的针刺效应比较.针刺研究,1994：19(1)：75-78
58. Bos JD, Kapsenberg ML. The skin immune system (SIS):its cellular constituents and their interactions. Immunol Today 1986; 7:235-40.
59. Nickoloff BJ. Dermal Immune System. Boca Raton:CRC Press,1993;
60. Bos JD. Skin Immune System (SIS). In:Bos JD(Ed.) Skin Immune System (SIS): Cutaneous Immunology and Clinical Immunodermatology. CRC Press, Boca Raton,2005:3-17
61. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease.Nat Rev Immunol.2009;9(10):679-91
62. Dirk Roosterman, Tobias Goerge, Stefan W.et al.Neuronal Control of Skin Function:The Skin as a Neuroimmunoendocrine Organ. Physiol. Rev.2006; 86: 1309-1379.
63.曹序茂.免疫功能与衰老[J].解放军健康,2000,(3)：20-21.
64. Ogra PL. Ageing and its possible impact on mucosal immune responses. Ageing ResRev.2010;9(2):101-6.
65. Nigam Y, Knight J.Exploring the anatomy and physiology of ageing. Part 9--The immune system.Nurs Times.2008;104(47):58-9
66. Herman WA, Lacka K.Pol Ageing and immune system Arch Med Wewn. 2004;112(6):1487-96.
67. Bauer ME. Stress, glucocorticoids and ageing of the immune system.Stress. 2005;8(1):69-83.
68. Wilder RL, et al. Neuroendocrine hormonal factors in rheumatoid arthritis and related conditions. Curr Opin Rheumatol,1990; 2(3):436-40
69. Harkness JA, et al. Circadian variation in disease activity in rheumatoid arthritis. Br Med J,1982(6315); 284:551-4
70. Neeck G, et al. Adrenal secretion of cortisol in patients with rheumatoid arthritis. J Rheumatol,1990; 17(1):24-9
71. Hall J, et al. Abnormal hypothalamic-pituitary-adrenal axis function in rheumatoid arthritis. Effects of nonsteroidal antiinflammatory drugs and water immersion. Arthritis Rheum,1994; 37(8):1132-7
72. Jorgensen C, et al. Dysregulation of the hypothalamo-pituitary axis in rheumatoid arthritis. J Rheumatol,1995; 22(10):1829-33
73. Baerwald CG, et al. Neurohumoral mechanisms in rheumatoid arthritis. Scand J Rheumatol,1997; 26(1):1-3
74. Gudbjornsson B, et al. Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis. Effect of glucocorticoids J Rheumatol,1996; 23(4):596-602
75. Jorundsson E, Press CM, Landsverk T. Distribution of MHC-Ⅱ and CD1 molecules in the skin of lambs and changes during experimentally-induced contact hypersensitivity.Vet Immunol Immunopathol.2000;74(1-2):87-101.
76. Gelin C, Sloma I, Charron D, et al. Regulation of MHC Ⅱ and CD1 antigen presentation:from ubiquity to security.J Leukoc Biol.2009;85(2):215-24
77. Melian A, Beckman EM, Porcelli SA, et al. Antigen presentation by CD1 and MHC-encoded class Ⅰ-like molecules.Curr Opin Immunol.1996;8(1):82-8.
78. Zabka TS, Romano TA. Distribution of MHC Ⅱ (+) cells in skin of the Atlantic bottlenose dolphin (Tursiops truncatus):an initial investigation of dolphin dendritic cells.Anat Rec A Discov Mol Cell Evol Biol.2003;273(1):636-47.
79. Cocco C, Pistoia V, Airoldi I.New perspectives for melanoma immunotherapy: role of IL-12.Curr Mol Med.20099(4):459-69.
80. Meeran SM, Katiyar N, Singh T, et al.Loss of endogenous interleukin-12 activates survival signals in ultraviolet-exposed mouse skin and skin tumors.Neoplasia. 2009;11(9):846-55.
81. Katiyar SK. Interleukin-12 and photocarcinogenesis.Toxicol Appl Pharmacol. 2007;224(3):220-7.
82. SelvakarAt et aL. lnmmnogetic,1992; 36:175
83.BordelloF et al.J Inmmnol·1994; 153:5038
84. Van de Ven R, Lindenberg JJ, Oosterhoff D, et al. Selective transduction of mature DC in human skin and lymph nodes by CD80/CD86-targeted fiber-modified adenovirus-5/3. J Immunother.2009;32(9):895-906.
85. Byrne SN, Halliday GM. High levels of Fas ligand and MHC class Ⅱ in the absence of CD80 or CD86 expression and a decreased CD4+ T cell Infiltration,enables murine skin tumours to progress. Cancer Immunol Immunother.2003;52(6):396-402.
86. Ossevoort MA, Lorre K, Boon L, et al. Prolonged skin graft survival by administration of anti-CD80 monoclonal antibody with cyclosporin A. J Immunother.1999;22(5):381-9.
87. Williams IR, Ort RJ, Daley D, et al.Constitutive expression of B7-1 (CD80) on mouse keratinocytes does not prevent development of chemically induced skin papillomas and carcinomas. J Immunol.1996;156(9):3382-8.
88. Mitra RS, Judge TA, Nestle FO, et al. Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7-1 (CD8o) and B7-2 (CD86) expression. J Immunol.1995;154(6):2668-77.
89. Esteban MA, Rodriguez A, Ayala AG, et al. Effects of high doses of cortisol on innate cellular immune response of seabream (Sparus aurata L.).Gen Comp Endocrinol.2004;137(1):89-98.
90. Kueper T, Grune T, Muhr GM, et al.Modification of vimentin:a general mechanism of nonenzymatic glycation in human skin. Ann N Y Acad Sci. 2008;1126:328-32.
91. Kueper T, Grune T, Prahl S, et al. Vimentin is the specific target in skin glycation. Structural prerequisites,functional consequences, and role in skin aging. J Biol Chem.2007;282(32):23427-36.
92. Hashimoto M, Inoue S, Ogawa S, et al.Rapid fragmentation of vimentin in human skin fibroblasts exposed to tamoxifen:a possible involvement of caspase-3. Biochem Biophys Res Commun.1998;247(2):401-6.
93. Bavdek SV, Golob Z, van Dijk J, et al. Vimentin- and desmin-positive cells in the moulting budgerigar (Melopsittacus undulatus) skin. Anat Histol Embryol. 1997;26(3):173-8.
94. Iyer PV, Leong AS. Poorly differentiated squamous cell carcinomas of the skin can express vimentin. J Cutan Pathol.1992;19(1):34-9.
95. Hosaka K, Ryu J, Saitoh S, et al. The combined effects of anti-TNFalpha antibody and IL-1 receptor antagonist in human rheumatoid arthritis synovial membrane.Cytokine.2005;32(6):263-9.
96. Raffeiner B, Botsios C, Ometto F,et al. TNFalpha blockers and infectious risk in rheumatoid arthritis.Reumatismo.2009;61(3):165-73.
97. Xu S, Lu H, Lin J, et al Regulation of TNFalpha and IL1beta in rheumatoid arthritis synovial fibroblasts by leukotriene B4. Rheumatol Int.2009. [Epub ahead of print] PubMed PMID:19809821.
98. Scrivo R, Conti F, Spinelli FR, et al. Switching between TNFalpha antagonists in rheumatoid arthritis:personal experience and review of the literature. Reumatismo. 2009;61(2):107-17.
99. Machado P, Santos A, Pereira C,et al.Increased prevalence of allergic sensitisation in rheumatoid arthritis patients treated with anti-TNFalpha. Joint Bone Spine. 2009;76(5):508-13.
100. Brocq O, Millasseau E, Albert C, et al.Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine.2009;76(4):350-5.
101. Kehlen A, Lauterbach R, Santos AN, et al. IL-1 beta- and IL-4-induced down-regulation of autotaxin mRNA and PC-1 in fibroblast-like synoviocytes of patients with rheumatoid arthritis (RA). Clin Exp Immunol.2001;123(1):147-54.
102. Punzi L, Pianon M, Bertazzolo N,et al.Interrelationship between synovial fluid interleukin (IL)-6, IL-1 beta and disease activity indices in rheumatoid arthritis. Rheumatol Int.1994;14(2):83-4.
103. Zangerle PF, De Groote D, Lopez M, et al. Direct stimulation of cytokines (IL-1 beta,TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood:Ⅱ. Application to rheumatoid arthritis and osteoarthritis. Cytokine. 1992;4(6):568-75.
104. Ruschen S, Lemm G, Warnatz H. Spontaneous and LPS-stimulated production of intracellular IL-1 beta by synovial macrophages in rheumatoid arthritis is inhibited by IFN-gamma. Clin Exp Immunol.1989;76(2):246-51.
105. Alanara T, Karstila K, Moilanen T, Set al. Expression of IL-10 family cytokines in rheumatoid arthritis:elevated levels of IL-19 in the joints. Scand J Rheumatol.2010;39(2):118-26.
106. Heo YJ, Joo YB, Oh HJ, et al. IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4+ T cell population of rheumatoid arthritis patients. Immunol Lett.2010;127(2):150-6.
107. Hussein MR, Fathi NA, El-Din AM, et al. Alterations of the CD4(+), CD8 (+) T cell subsets, interleukins-lbeta, IL-10, IL-17, tumor necrosis factor-alpha and soluble intercellular adhesion molecule-1 in rheumatoid arthritis and osteoarthritis: preliminary observations. Pathol Oncol Res.2008;14(3):321-8.
108. Mitchell A, Rentero C, Endoh Y, et al. LILRA5 is expressed by synovial tissue macrophages in rheumatoid arthritis, selectively induces pro-inflammatory cytokines and IL-10 and is regulated by TNF-alpha, IL-10 and IFN-gamma. Eur J Immunol.2008;38(12):3459-73.
109. Moreno OM, Gonzalez CI, Saaibi DL, et al.Polymorphisms of IL-10 gene promoter and rheumatoid arthritis in a Colombian population. Biomedica. 2007;27(1):56-65.
110. Litinsky I, Paran D, Levartovsky D, et al. The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. Cytokine.2006;33(2):106-10.
111. Miellot A, Zhu R, Diem S, et al. Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway. Eur J Immunol.2005;35(12):3704-13.
112. Yamana J, Yamamura M, Okamoto A, et al.Resistance to IL-10 inhibition of interferon gamma production and expression of suppressor of cytokine signaling 1 in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res Ther. 2004;6(6):R567-77.
113. Appel H, Neure L, Kuhne M, et al. An elevated level of IL-10- and TGFbeta-secreting T cells, B cells and macrophages in the synovial membrane of patients with reactive arthritis compared to rheumatoid arthritis.Clin Rheumatol. 200423(5):435-40.
114. Foey AD, Field S, Ahmed S, et al. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production:implications for rheumatoid arthritis. Arthritis Res Ther.2003;5(6):R317-28.
115. Bodman-Smith MD, Corrigall VM, Kemeny DM, et al. BiP, a putative autoantigen in rheumatoid arthritis, stimulates IL-10-producing CD8-positive T cells from normal individuals. Rheumatology (Oxford).2003;42(5):637-44.
116. Verhoef CM, van Roon JA, Vianen ME, et al. Interleukin 10(IL-10), not IL-4 or interferon-gamma production, correlates with progression of joint destruction in rheumatoid arthritis. J Rheumatol.2001;28(9):1960-6.
117. Eskdale J, McNicholl J, Wordsworth P, et al. Interleukin-10 microsatellite polymorphisms and IL-10 locus alleles in rheumatoid arthritis susceptibility. Lancet.1998;352(9136):1282-3.
118. Keystone E, Wherry J, Grint P. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am.1998;24(3):629-39.
119. Hajeer AH, Lazarus M, Turner D, et al. IL-10 gene promoter polymorphisms in rheumatoid arthritis. Scand J Rheumatol.1998;27(2):142-5.
120. Raziuddin S, Bahabri S, Al-Dalaan A, et al. A mixed Th1/Th2 cell cytokine response predominates in systemic onset juvenile rheumatoid arthritis: immunoregulatory IL-10 function. Clin Immunol Immunopathol. 1998;86(2):192-8.
121. Al-Janadi M, al-Dalaan A, al-Balla S, et al.Interleukin-10 (IL-10) secretion in systemic lupus erythematosus and rheumatoid arthritis:IL-10-dependent CD4+CD45RO+ T cell-B cell antibody synthesis. J Clin Immunol. 1996;16(4):198-207.
122. Bucht A, Larsson P, Weisbrot L, et al. Expression of interferon-gamma (IFN-gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA). Clin Exp Immunol.1996;103(3):357-67.
123. 杨慎峭,刘旭光,余曙光,等.艾灸对类风湿性关节炎家兔关节滑膜液IL-1β, TNF-α含量的影响.成都中医药大学学报.2005,28(3)：11-12
124. 杨慎峭,房繁恭,王海军,等.灸法治疗类风湿关节炎临床与实验研究述评.中医药学刊.2004,22(11)：2109-2110
125. 王磊,李学武等.艾灸疗法作用机理国内外研究进展.中国针灸.2001,21(9)：567-570
126. Villanueva EC, Myers MG Jr. Leptin receptor signaling and the regulation of mammalian physiology. Int J Obes (Lond).2008;32 Suppl 7:S8-12.
127. Tanaka T, Masuzaki H, Ebihara K, et al. Clinical and biological consequences of leptin receptor mutation]. Nippon Rinsho.2006;Suppl3:241-8.
128. Leshan RL, Bjornholm M, Munzberg H, et al. Leptin receptor signaling and action in the central nervous system. Obesity (Silver Spring).2006; 14 Suppl 5:208S-212S.
129. Ebihara K, Nakao K. Leptin gene and leptin receptor gene]. Nippon Rinsho.2006;64 Suppl 5:391-5.
130. Myers MG Jr. Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog Horm Res.2004;59:287-304.
131. Bates SH, Myers MG Jr. The role of leptin receptor signaling in feeding and neuroendocrine function. Trends Endocrinol Metab.2003;14(10):447-52.
132. Halle M, Persson PB. Role of leptin and leptin receptor in inflammation. Am J Physiol Regul Integr Comp Physiol.2003;284(3):R760-2.
133. Ogawa Y, Nakao K. Leptin and leptin receptor. Nippon Rinsho. 2002;60Suppl 7:571-6.
134. Heshka JT, Jones PJ. A role for dietary fat in leptin receptor, OB-Rb,function. Life Sci.2001;69(9):987-1003.
135. Nishimura H, Ogawa Y, Nakao K. Structures and functions of leptin and leptin receptor. Nippon Rinsho.2001;59 Suppl 2:509-14.
136. Targonska-Stepniak B, Dryglewska M, Majdan M. Adiponectin and leptin serum concentrations in patients with rheumatoid arthritis. Rheumatol Int. 2010;30(6):731-7.
137. Derdemezis CS, Filippatos TD, Voulgari PV, et al.Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis. Fundam Clin Pharmacol.2009;23(5):595-600.
138. Popa C, Netea MG, de Graaf J, et al.Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. J Rheumatol.2009;36(4):724-30.
139. Aguilar-Chavez EA, Gamez-Nava JI, Lopez-Olivo MA, et al. Circulating leptin and bone mineral density in rheumatoid arthritis. J Rheumatol. 2009;36(3):512-6.
140. Seven A, Guzel S, Aslan M, et al. Serum and synovial fluid leptin levels and markers of inflammation in rheumatoid arthritis. Rheumatol Int. 2009;29(7):743-7.
141. Targonska-Stepniak B, Majdan M, Dryglewska M. Leptin serum levels in rheumatoid arthritis patients:relation to disease duration and activity. Rheumatol Int.2008;28(6):585-91.
142. Wislowska M, Rok M, Jaszczyk B, et al. Serum leptin in rheumatoid arthritis. Rheumatol Int.2007;27(10):947-54.
143. Lee SW, Park MC, Park YB, et al. Measurement of the serum leptin level could assist disease activity monitoring in rheumatoid arthritis. Rheumatol Int. 2007;27(6):537-40.
144. Hizmetli S, Kisa M, Gokalp N, et al. Are plasma and synovial fluid leptin levels correlated with disease activity in rheumatoid arthritis? Rheumatol Int. 2007;27(4):335-8.
145. Gunaydin R, Kaya T, Atay A, et al. Serum leptin levels in rheumatoid arthritis and relationship with disease activity. South Med J.2006;99(10):1078-83.
146. Salazar-Paramo M, Gonzalez-Ortiz M, Gonzalez-Lopez L, et al. Serum leptin levels in patients with rheumatoid arthritis. J Clin Rheumatol.2001;7(1):57-9.
147. Toussirot E, Nguyen NU, Dumoulin G, et al. Relationship between growth hormone-IGF-I-IGFBP-3 axis and serum leptin levels with bone mass and body composition in patients with rheumatoid arthritis.Rheumatology (Oxford). 2005;44(1):120-5.
148. Harle P, Pongratz G, Weidler C, et al. Possible role of leptin in hypoandrogenicity in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis.2004;63(7):809-16.
149. Bokarewa M, Bokarew D, Hultgren O, et al. Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62(10):952-6.
150. Fraser DA, Thoen J, Bondhus S, et al. Reduction in serum leptin and IGF-1 but preserved T-lymphocyte numbers and activation after a ketogenic diet in rheumatoid arthritis patients.Clin Exp Rheumatol.2000;18(2):209-14.
151. 陈啸峰.电针治疗单纯性肥胖及对血清瘦素和胰岛素影响的研究.针灸临床杂志.2009,25(8)：3-5
152. 王澍欣,李艳慧.穴位埋线对肥胖模型大鼠瘦素水平及血脂的影响.天津中医药.2009,26(1)：63-65
153. 钟国存.针灸治疗单纯性肥胖临床及机理研究进展.山西中医学院学报.2007,8(5)：55-57
154. 刘敏,陆亚康,戴利成等.针药并用治疗单纯性肥胖的临床研究.中国中医药科技.2009(3)：169-170
155. 龚美蓉,徐斌,毛珍等.针刺对肥胖模型大鼠下丘脑瘦素受体mRNA的表达与针刺的影响.中国组织工程研究与临床康复.2008,12(46)：9105-9108
156. 李建武,刘建民,熊源胤等.针灸对类风湿性关节炎神经-内分泌-免疫网络调节作用的研究进展.中医研究.2006,19(3)：57-60
157. 施茵,周珊玲.足三里穴对神经—内分泌—免疫网络的调节作用.江西中医学院学报.2003,15(2)：37-39
158. 刘心莲,尹淑英针灸对类风湿性关节炎患者免疫—神经—内分泌系统影响的临床研究.中国针灸.1997,17(9)：529-531.
159. 李辉,李晓泓.神经肽对针灸免疫调节影响的研究进展.上海针灸杂志.2003,22(3)：41-44
160.唐照亮,余新欢等.6—羟色多巴胺化学损毁小鼠外周交感神经对艾灸免疫调节作用的影响.针刺研究.2001,26(4)：299-302.
1.杨力强,李晓红,邓柏颖.化脓灸对感冒易感患者T细胞亚群影响的研究[J].新中医,2008,40(9)：74-75
2.吴炳煌,吴明霞,林宏等.隔姜灸神阚治疗支气管哮喘疗效与T细胞亚群含量变化关系的分析[J].中国针灸,1997,17(7)：389
3.王松梅,李兴国,张立群.神阙隔药灸疗法治疗溃疡性结肠炎的临床观察[J].中国针灸,2006,26(2)：97-99
4.鞠琰莉,王黎,刘金芝等.电针、艾灸、埋线对痛经大鼠T细胞亚群水平的影响[J].上海针灸杂志,2007,26(9)：43-46
5.曹毅,马泽云,郭平.艾灸阿是穴对多发性跖疣患者细胞免疫功能的调节作用[J].浙江中医学院学报,2004,28(4)：64
6.袁民,傅莉萍,陈雪华等.艾灸对荷瘤小鼠免疫功能的影响[J].针刺研究,2003,28(2)：11
7.成拯,姜翼,陈凯.放化疗法配合艾灸神阙穴治疗晚期鼻咽癌42例近期疗效观察[J].新中医,2005,37(4)：58-59
8.周立华,卢依平.从艾灸治疗艾滋病腹泻看艾灸治艾优势[J].河南中医学院学报,2005,20(3)：4-5
9.徐兰凤,喻志冲,沈梅红.艾灸对60例食道癌放疗患者免疫功能的影响[J].2008,24(1)：12-14
10.邓宏,龙顺钦,吴万垠等.艾灸防治化疗致白细胞减少症46例疗效观察[J].新中医,2007,39(6)：90-92
11.郑雪峰,聂焱,王志强.艾灸关元穴对化疗后低白细胞模型大鼠外周血象影响的实验研究[J].湖北中医杂志,2009,31(5)：5-6
12.崔瑾,严洁.艾灸或针刺膈俞穴对环磷酰胺致白细胞减少大鼠诱生粒细胞一巨噬细胞集落刺激因子的作用[J].中国组织工程研究与临床康复,2007,11(28)：5473-5476
13.张帆,林周杰,黄镜招.灸治关元穴对阳虚患者不同时辰红细胞免疫功能影响[J].医学信息,2009；1(8)：7-8
14.沈梅红,徐兰凤,詹臻等.艾灸对放疗宫颈癌患者的红细胞免疫粘附功能和TNF的影响[J].安徽中医临床杂志,2002,14(5)：352-353
15.钱卫华.针刺五脏夹脊穴对红细胞免疫功能影响的实验研究[J].针灸临床杂志,1995,11(5)：30-33
16.宋小鸽,唐照亮,侯正明.艾灸对吗啡戒断小鼠红细胞免疫功能的调节作用[J].针刺研究,2000,6(9)：51-53
17.田华张,陈俊玲.艾灸强壮穴对慢性疲劳综合征患者免疫功能的影响[J].深圳中西医结合杂志,2006,16(4)：225-226
18.居贤水,赵粹英.艾灸延缓衰老的临床观察[J].上海针灸杂志,1995,3：22-23
19.邱幸生,陈凯,佟丽.灸神阙穴对移植瘤小鼠血清白细胞介素12及NK细胞活性的影响[J].中医杂志,2003,44(3)：186-187
20.宋小鸽,唐照亮,金敖兴等.艾灸对吗啡依赖小鼠细胞免疫功能的影响[J].针刺研究,1999,24(4)：29
21.邢红梅,祝佩芹,李建茹.健脾补肾中药配合穴位艾灸治疗卵巢早衰的临床研究[J].新中医,2007,39(4)：26-27
22.虞永志.艾灸对宫颈癌放疗患者免疫球蛋白的影响[J].中毕现代中西医杂志,2003,8(1)：719-720
23.喻志冲,徐兰风,詹臻.艾灸对宫颈癌放疗患者免疫球蛋白的影响[J].上海针灸杂志,2002,21(6)：15-16
24.吴焕淦,王景辉,陈汉平等.隔药灸治疗肠易激综合征的疗效与免疫学机理初探[J].中国针灸,1996,2：43
25.李红,朱梅菊,高顺生.针灸足三里穴对小鼠运动能力及部分免疫指标的影响[J].中国运动医学杂志,2004,23(1)：42-45
26.邓柏颖,杨力强,罗敏然.化脓灸提高“体虚易感”患者免疫力的临床研究[J].四川中医,2005,23(1)：86-87
27.高希言,封丽华,李卫红等.艾灸督脉穴对亚急性衰老小鼠自由基与免疫器官的影响[J].河南中医学院学报,2003,18(5)：22
28.黄哗,尚明华.艾灸足三里穴对腹泻小鼠脾,胸腺重量的影响[J].山西中医,1997,13(5)：41-42
29.吴娟,胥志斌,占国.化脓灸对免疫性慢性肝损伤小鼠免疫功能的影响[J].中医药管理杂志,2007,15(4)：283-285
30.周鹏,赵仓焕.浅谈灸法在“治未病”中的应用[J].时珍国医国药,2006, 17(5)：865-866
31.王慧.逆灸应激法预防传染性非典型肺炎初探[J].中医研究,2003,16(5)： 52
32.高树中.隔药灸脐法延缓衰老临床观察[J].中国针灸,2007,27(6)：398
33.李晓泓.逆灸关元穴对自然更年期大鼠下丘脑雌激素受体a和促肾E腺激素释放激素及血浆促肾上腺激素的调节[J].中国临床康复,2006,10(7)：118
34.李晓泓.逆灸关元穴对不同月龄更年期大鼠肿瘤坏死因子a及脾脏雌激素受体a的影响[J].中国临床康复,2006,10(43)：171
35.李晓泓.逆灸对自然更年期大鼠子宫组织形态及EZ,P和ER-a影响的实验研究[J].北京中医药大学学报,2006,29(8)：558